Conditions: Retraction of Colostomy
Keywords: Ileostomy reversal
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 47
Healthy volunteers: no

Brief summary:
This study is designed to compare the standard of care against EXPAREL (bupivacaine liposome injectable suspension) to determine if total opioid consumption is reduced when using EXPAREL, therefore possibly reducing total hospitalization costs.

Detailed description:
This is a phase 4, prospective, sequential, open-label study designed to evaluate the efficacy, safety, and health economic benefits of intraoperative local wound infiltration with EXPAREL (bupivacaine liposome injectable suspension) compared with postsurgical administration of standardized intravenous (IV) morphine sulfate or Sponsor-approved equivalent for postsurgical analgesia in adult patients undergoing ileostomy reversal with general anesthesia.

Arms:
arm 1: IV Morphine sulfate or Sponsor-approved equivalent via a patient-controlled analgesia (PCA) pump arm 2: bupivacaine liposome injectable suspension.

Interventions: intervention 1: Group 1 Standard of Care intervention 2: Group 2 EXPAREL
Intervention descriptions: intervention 1: Patients in this group will receive IV morphine sulfate or Sponsor-approved equivalent via PCA pump, as needed. intervention 2: Patients in this group will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 30cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.

Protocol document: